High drug related mortality rates following prison release: Assessing the acceptance likelihood of a naltrexone injection and related concerns.

Philip Murphy, Faizal Mohammed, Michelle Wareing, Angela Cotton, John McNeil, Paula Irving, Steve Jones, Louisa Sharples, Rebecca Monk, Peter Elton

Research output: Contribution to journalArticle

8 Downloads (Pure)

Abstract

Background and aims. High drug related mortality amongst former prisoners in the 4 weeks following release is an internationally recognised problem. Naltrexone injections at release could diminish this by blockading opioid receptors, but naltrexone is not licenced for injection for treating opiate misuse in the United Kingdom and some other countries. This study examined the likelihood of accepting a naltrexone injection at release, and the relationship of this likelihood to other relevant variables. Method. Sixty-one male prisoners with a history of heroin use, who were approaching release from two prisons in the north-west of England, provided likelihood ratings for accepting a naltrexone injection if it were to have been available. Additional data was gathered regarding demographic and drug use histories, and also from psychometric instruments relevant to drug misuse and treatment preparedness. Results. Maximum likelihood ratings for accepting a naltrexone injection were recorded by 55.7% of the sample with only 9.8% indicating no likelihood of accepting an injection. Likelihood ratings were positively related to serving a current sentence for an acquisitive offence compared to drug related or violence offences, and negatively related to peak methadone dosages during the current sentence. Conclusions. Although naltrexone injections were not available to participants in this study, the findings suggest that the potential uptake for this intervention is sufficient to warrant a clinical trial with this population of British prisoners, with a view to potential changes to its current licencing status. However, the importance of individual patient readiness for such an abstinence orientated intervention is emphasised by the negative correlation between the likelihood ratings and recent methadone doses.
Original languageEnglish
Pages (from-to)91-98
JournalJournal of Substance Abuse
Volume92
Early online date4 Jul 2018
DOIs
Publication statusE-pub ahead of print - 4 Jul 2018

Fingerprint

Naltrexone
Prisons
Injections
Mortality
Prisoners
Pharmaceutical Preparations
Methadone
Opiate Alkaloids
Heroin
Opioid Receptors
Licensure
Psychometrics
Violence
England
Demography
Clinical Trials
Population

Keywords

  • Heroin
  • Prisoners
  • Death
  • Naltrexone
  • Injections
  • Readiness

Cite this

Murphy, Philip ; Mohammed, Faizal ; Wareing, Michelle ; Cotton, Angela ; McNeil, John ; Irving, Paula ; Jones, Steve ; Sharples, Louisa ; Monk, Rebecca ; Elton, Peter. / High drug related mortality rates following prison release: Assessing the acceptance likelihood of a naltrexone injection and related concerns. In: Journal of Substance Abuse. 2018 ; Vol. 92. pp. 91-98.
@article{60dea0ade3a94ae9ac787d11e0bd2290,
title = "High drug related mortality rates following prison release: Assessing the acceptance likelihood of a naltrexone injection and related concerns.",
abstract = "Background and aims. High drug related mortality amongst former prisoners in the 4 weeks following release is an internationally recognised problem. Naltrexone injections at release could diminish this by blockading opioid receptors, but naltrexone is not licenced for injection for treating opiate misuse in the United Kingdom and some other countries. This study examined the likelihood of accepting a naltrexone injection at release, and the relationship of this likelihood to other relevant variables. Method. Sixty-one male prisoners with a history of heroin use, who were approaching release from two prisons in the north-west of England, provided likelihood ratings for accepting a naltrexone injection if it were to have been available. Additional data was gathered regarding demographic and drug use histories, and also from psychometric instruments relevant to drug misuse and treatment preparedness. Results. Maximum likelihood ratings for accepting a naltrexone injection were recorded by 55.7{\%} of the sample with only 9.8{\%} indicating no likelihood of accepting an injection. Likelihood ratings were positively related to serving a current sentence for an acquisitive offence compared to drug related or violence offences, and negatively related to peak methadone dosages during the current sentence. Conclusions. Although naltrexone injections were not available to participants in this study, the findings suggest that the potential uptake for this intervention is sufficient to warrant a clinical trial with this population of British prisoners, with a view to potential changes to its current licencing status. However, the importance of individual patient readiness for such an abstinence orientated intervention is emphasised by the negative correlation between the likelihood ratings and recent methadone doses.",
keywords = "Heroin, Prisoners, Death, Naltrexone, Injections, Readiness",
author = "Philip Murphy and Faizal Mohammed and Michelle Wareing and Angela Cotton and John McNeil and Paula Irving and Steve Jones and Louisa Sharples and Rebecca Monk and Peter Elton",
year = "2018",
month = "7",
day = "4",
doi = "10.1016/j.jsat.2018.07.002",
language = "English",
volume = "92",
pages = "91--98",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier",

}

High drug related mortality rates following prison release: Assessing the acceptance likelihood of a naltrexone injection and related concerns. / Murphy, Philip; Mohammed, Faizal; Wareing, Michelle; Cotton, Angela; McNeil, John; Irving, Paula; Jones, Steve; Sharples, Louisa; Monk, Rebecca; Elton, Peter.

In: Journal of Substance Abuse, Vol. 92, 04.07.2018, p. 91-98.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High drug related mortality rates following prison release: Assessing the acceptance likelihood of a naltrexone injection and related concerns.

AU - Murphy, Philip

AU - Mohammed, Faizal

AU - Wareing, Michelle

AU - Cotton, Angela

AU - McNeil, John

AU - Irving, Paula

AU - Jones, Steve

AU - Sharples, Louisa

AU - Monk, Rebecca

AU - Elton, Peter

PY - 2018/7/4

Y1 - 2018/7/4

N2 - Background and aims. High drug related mortality amongst former prisoners in the 4 weeks following release is an internationally recognised problem. Naltrexone injections at release could diminish this by blockading opioid receptors, but naltrexone is not licenced for injection for treating opiate misuse in the United Kingdom and some other countries. This study examined the likelihood of accepting a naltrexone injection at release, and the relationship of this likelihood to other relevant variables. Method. Sixty-one male prisoners with a history of heroin use, who were approaching release from two prisons in the north-west of England, provided likelihood ratings for accepting a naltrexone injection if it were to have been available. Additional data was gathered regarding demographic and drug use histories, and also from psychometric instruments relevant to drug misuse and treatment preparedness. Results. Maximum likelihood ratings for accepting a naltrexone injection were recorded by 55.7% of the sample with only 9.8% indicating no likelihood of accepting an injection. Likelihood ratings were positively related to serving a current sentence for an acquisitive offence compared to drug related or violence offences, and negatively related to peak methadone dosages during the current sentence. Conclusions. Although naltrexone injections were not available to participants in this study, the findings suggest that the potential uptake for this intervention is sufficient to warrant a clinical trial with this population of British prisoners, with a view to potential changes to its current licencing status. However, the importance of individual patient readiness for such an abstinence orientated intervention is emphasised by the negative correlation between the likelihood ratings and recent methadone doses.

AB - Background and aims. High drug related mortality amongst former prisoners in the 4 weeks following release is an internationally recognised problem. Naltrexone injections at release could diminish this by blockading opioid receptors, but naltrexone is not licenced for injection for treating opiate misuse in the United Kingdom and some other countries. This study examined the likelihood of accepting a naltrexone injection at release, and the relationship of this likelihood to other relevant variables. Method. Sixty-one male prisoners with a history of heroin use, who were approaching release from two prisons in the north-west of England, provided likelihood ratings for accepting a naltrexone injection if it were to have been available. Additional data was gathered regarding demographic and drug use histories, and also from psychometric instruments relevant to drug misuse and treatment preparedness. Results. Maximum likelihood ratings for accepting a naltrexone injection were recorded by 55.7% of the sample with only 9.8% indicating no likelihood of accepting an injection. Likelihood ratings were positively related to serving a current sentence for an acquisitive offence compared to drug related or violence offences, and negatively related to peak methadone dosages during the current sentence. Conclusions. Although naltrexone injections were not available to participants in this study, the findings suggest that the potential uptake for this intervention is sufficient to warrant a clinical trial with this population of British prisoners, with a view to potential changes to its current licencing status. However, the importance of individual patient readiness for such an abstinence orientated intervention is emphasised by the negative correlation between the likelihood ratings and recent methadone doses.

KW - Heroin

KW - Prisoners

KW - Death

KW - Naltrexone

KW - Injections

KW - Readiness

U2 - 10.1016/j.jsat.2018.07.002

DO - 10.1016/j.jsat.2018.07.002

M3 - Article

VL - 92

SP - 91

EP - 98

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

ER -